Stock Update (NYSE:AGN): Allergan Announces OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) Now Approved in the European Union for the Treatment of Diabetic Macular Edema

[Business Wire] – Allergan, Inc. announced today that the European Commission has extended the Marketing Authorization for OZURDEX® (dexamethasone 700 mcg intravitreal implant in applica Read more on this. Allergan Inc. (AGN), . . . → Read More: Stock Update (NYSE:AGN): Allergan Announces OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) Now Approved in the European Union for the Treatment of Diabetic Macular Edema Similar Articles: Company Update (NYSE:ACE): ACE Aviation reports second quarter results and provides an update on its liquidation process Company Update: Allergan Inc (NYSE:AGN) – Valeant, Ackman to submit Allergan special meeting request-CNBC Market Update: Allergan Inc (NYSE:AGN) – Valeant Extends Offer To Acquire Allergan